Search results
Results From The WOW.Com Content Network
File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
Medical bottles and syringe are seen with Novartis logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022.
Former logo. Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd [3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its ...
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ). [9] [7]
Revenue. $1.921 billion (2005) Number of employees. 5,400 (2005) Website. www.chiron.com. Chiron Corporation ( / ˈkaɪrɒn / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five ...
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...